Current status of nanodrug carriers for targeted therapy of gliomas in the brain

Junjun Luo

doi:10.1117/12.3013053

8 January 2024 Current status of nanodrug carriers for targeted therapy of gliomas in the brain

Junjun Luo

Author Affiliations +

Proceedings Volume 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023); 129241R (2024) https://doi.org/10.1117/12.3013053
Event: 3rd International Conference on Biological Engineering and Medical Science (ICBioMed2023), 2023, ONLINE, United Kingdom

Abstract

Glioma is the most common primary craniocerebral malignant tumour arising from the cancerous transformation of glial cells in the brain and spinal cord. It is characterized by high morbidity, high recurrence rate, high mortality rate, and low cure rate. Due to the existence of the blood-brain barrier (BBB), it is difficult for many therapeutic drugs to reach the brain tumour tissues, making traditional surgery, radiotherapy, and chemotherapy ineffective. Therefore, the invention of modern nanocarriers has led to new developments in the treatment of gliomas. In this paper, the mechanism of nanomedicine penetrating the blood-brain barrier is outlined. And then, the two major categories of organic and inorganic nanomedicine carriers are introduced. Meanwhile, the specific targeting of nanomedicine and gene carriers for glioma is described. Finally, the current status of nanomedicine carriers is summarised and the future development direction of nanomedicine carriers is proposed. This paper provides a comprehensive overview of nanodrug delivery systems applied in targeted glioma therapy.

(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.

Citation Download Citation

Junjun Luo "Current status of nanodrug carriers for targeted therapy of gliomas in the brain", Proc. SPIE 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), 129241R (8 January 2024); https://doi.org/10.1117/12.3013053

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

;

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE